Drug intelligence / Profile preview

GLPG4059

Development stage: Phase 1
Lead developer: Galapagos
Modality: Small Molecules
Administration: Oral

Overview

GLPG4059 is an investigational small molecule drug that was developed by Galapagos for potential use in metabolic diseases, specifically type 2 diabetes. The compound acts as an inhibitor of Per-Arnt-Sim Kinase (PASK), a protein involved in the regulation of glucose levels in the body. By inhibiting PASK, GLPG4059 aims to lower blood sugar levels. The drug was administered orally and underwent Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. Development has since been discontinued[1][2][4].

Targets

PASK (Per-arnt-sim kinase)

Beyond the preview

Go deeper on GLPG4059.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLPG4059.

Explore the full profile